[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343466-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343466-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pelp1-is-a-novel-therapeutic-target-in-hepatocellular-carcinoma","PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma","","Hepatocellular carcinoma (HCC) remains a major cause of cancer mortality, with a median survival of about 10 months, creating an urgent need for effective targeted therapies. Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1) signaling has been linked to multiple cancers, but its role in HCC was unclear. Cancer Genome Atlas and IHC analyses show elevated PELP1 in tumors and worse survival with high expression. PELP1 suppression by short hairpin RNA reduces HCC cell viability, clonogenicity, and invasion, while the small-molecule inhibitor SMIP34 similarly impairs these malignant phenotypes. Mechanistically, PELP1 knockdown decreases c-Myc/E2F and related oncogenic programs and SMIP34 disrupts the Rix complex, a key ribosomal biogenesis component. In xenograft models, PELP1 inhibition significantly slows tumor growth, supporting PELP1 as a promising therapeutic target and suggesting SMIP34-like PELP1-targeted drugs for HCC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pelp1-is-a-novel-therapeutic-target-in-hepatocellular-carcinoma/343466/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pelp1-is-a-novel-therapeutic-target-in-hepatocellular-carcinoma/343466.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What evidence links PELP1 to hepatocellular carcinoma progression?","Question",{"text":63,"@type":64},"Analysis of TCGA HCC gene expression datasets and IHC of HCC tissue microarrays shows higher PELP1 expression in tumors versus normal tissues, and high PELP1 correlates with unfavorable survival outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does inhibiting PELP1 affect HCC cells?",{"text":68,"@type":64},"PELP1 knockdown using short hairpin RNA significantly reduces HCC cell viability, clonogenicity, and invasion. The small-molecule inhibitor SMIP34 likewise decreases cell viability, clonogenic survival, and invasiveness.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism is proposed for SMIP34’s antitumor effects?",{"text":72,"@type":64},"RNA sequencing indicates reduced oncogenic pathways (including c-Myc and E2F) after PELP1 knockdown, and mechanistic studies show SMIP34 treatment impairs the Rix complex, a critical component of ribosomal biogenesis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343466,1790646729,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-24-0173](https://doi.org/10.1158/2767-9764.CRC-24-0173)  OPEN ACCESS  \nPELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma  \nKhaled Mohamed Nassar1, Xue Yang1, Adriana Baker1, Rahul Gopalam1, William C. Arnold1,  \nTimilehin T. Adeniran1, Marian H. Hernandez Fernandez1, Megharani Mahajan1, Zhao Lai2,3, Yidong Chen2,4, Gangadhara R. Sareddy1,6, Suryavathi Viswanadhapalli1,6, Lu-Zhe Sun5,6, Ratna K. Vadlamudi1,6,7, and Uday P. Pratap1,6  \n􀀶  \nABSTRACT  \nHepatocellular carcinoma (HCC) is one of the leading causes of cancerrelated deaths in the United States, with a median survival period of approximately 10 months. There is an urgent need for the development of effective targeted therapies for the treatment of HCC. Proline-, glutamic acid–, and leucine-rich protein 1 (PELP1) signaling is implicated in the progression of many cancers, although its specific contribution to the progression of HCC is not yet well understood. Analysis of The Cancer Genome Atlas HCC gene expression data sets and IHC analysis of HCC tissue microarray revealed that HCC tumors had elevated expression of PELP1 compared with normal tissues, and high expression of PELP1 is associated with unfavorable survival outcomes. Suppression of PELP1 expression using short hairpin RNA significantly reduced the cell viability, clonogenicity, and invasion of HCC cells. Importantly, SMIP34, a first-in-class small-molecule inhibitor targeting PELP1, effectively decreased the cell viability, clonogenic survival, and invasiveness of HCC cells. Gene expression analysis using RNA sequencing revealed that  \nPELP1 knockdown cells exhibited a decrease in c-Myc, E2F, and otheroncogenic pathways related to HCC. Mechanistic studies showed that SMIP34 treatment impaired the Rix complex, a critical component of ribosomal biogenesis, in HCC cells. Furthermore, the knockdown orpharmacologic inhibition of PELP1 significantly decelerated the HCC tumor growth in xenograft models. In summary, our study findings indicate that PELP1 could serve as a promising target for therapeutic intervention in HCC.  \nSignificance: HCC is one of the leading causes of cancer fatalities in the United States. Effective targeted therapeutics for HCC are urgently needed. In this study, we show that PELP1 proto-oncogene is crucial to HCC progression and that PELP1 inhibition reduced HCC cell proliferation in vitro and in vivo. Our results imply that PELP1-targeted drugs like SMIP34 may be useful as new therapeutic agents for HCC treatment.  \nIntroduction  \nHepatocellular carcinoma (HCC) is the fourth leading cause of cancerrelated deaths in the world and is the fastest growing cause of liver cancer  \n1Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, Texas. 2Greehey Children’s Cancer Research Institute, University of Texas Health San Antonio, San Antonio, Texas. 3Department of Molecular Medicine, University of Texas Health San Antonio, San Antonio, Texas. 4Department of Population Health Sciences, University of Texas Health San Antonio, San Antonio, Texas. 5Department of Cell Systems & Anatomy, University of Texas Health San Antonio, San Antonio, Texas. 6Mays Cancer Center, University of Texas Health San Antonio, San Antonio, Texas. 7Audie L. Murphy South Texas Veterans Health Care System, San Antonio, Texas.  \nCorresponding Authors: Ratna K. Vadlamudi, Department of Obstetrics and Gynecology, University of Texas Health San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229. E-mail: [vadlamudi@uthscsa.edu](vadlamudi@uthscsa.edu); and Uday P. Pratap, [pratap@uthscsa.edu](pratap@uthscsa.edu)  \ndoi: 10.1158/2767-9764.CRC-24-0173  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4. 0) license.  \n©2024 The Authors; Published by the American Association for Cancer Research  \ndeaths in the United States ( 1) . Globally, liver cancer accounts for appro","cbCaiiN21aDMHa3Z","https://ap.wps.com/l/cbCaiiN21aDMHa3Z","pdf",29059511,11,"English","# Abstract\n## Significance\n## Introduction\n## PELP1 Signaling in Hepatocellular Carcinoma","[{\"question\":\"What evidence links PELP1 to hepatocellular carcinoma progression?\",\"answer\":\"Analysis of TCGA HCC gene expression datasets and IHC of HCC tissue microarrays shows higher PELP1 expression in tumors versus normal tissues, and high PELP1 correlates with unfavorable survival outcomes.\"},{\"question\":\"How does inhibiting PELP1 affect HCC cells?\",\"answer\":\"PELP1 knockdown using short hairpin RNA significantly reduces HCC cell viability, clonogenicity, and invasion. The small-molecule inhibitor SMIP34 likewise decreases cell viability, clonogenic survival, and invasiveness.\"},{\"question\":\"What mechanism is proposed for SMIP34’s antitumor effects?\",\"answer\":\"RNA sequencing indicates reduced oncogenic pathways (including c-Myc and E2F) after PELP1 knockdown, and mechanistic studies show SMIP34 treatment impairs the Rix complex, a critical component of ribosomal biogenesis.\"}]","PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma | PDF",1790051247,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/999833bf28eb76cd2d5cdb372c81e461.webp",983,1263,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0378dfa6f352d1a55cb656e9d9696910.webp",982,1262,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d0014ed8bfcb7f95d0bfc97cf9428bb2.webp",981,1261,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92432777e07b600a00399b23de84e806.webp",980,1259]